Formulation development of inhalation powders for FK888 using the E-haler® to improve the inhalation performance at a high dose, and its absorption in healthy volunteers

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 59, Issue 1, 2005, Pages 25-33

  Nakate, Toshiomi ^a   Yoshida, Hiromitsu ^a   Ohike, Atsuo ^a   Tokunaga, Yuji ^a   Ibuki, Rinta ^a   Kawashima, Yoshiaki ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Dry powder inhaler; E haler; Multistage cascade impactor; Pulmonary absorption; Soft pellets, HPMC capsule

Indexed keywords

ALPHA LACTOSE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; PHAMATOSE;

AIRFLOW; ARTICLE; DRUG ABSORPTION; DRUG CAPSULE; DRUG FORMULATION; DRUG MEGADOSE; DRUG PELLET; FLOW RATE; INHALATION; PARTICLE SIZE; POWDER; POWDER INHALER;

ABSORPTION; ADMINISTRATION, INHALATION; ADULT; CHEMISTRY, PHARMACEUTICAL; DIPEPTIDES; HUMANS; INDOLES; LUNG; MALE; METERED DOSE INHALERS; POWDERS;

EID: 9644279431     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.08.004     Document Type: Article

References (16)

1. L. Borgström, and S. Newman Total and regional lung deposition of terbutaline sulphate via a pressurized MDI or via Turbuhaler Int. J. Pharm. 97 1993 47 53
2. O. Selroos, A. Pietinalho, and H. Riska Delivery devices for inhaled asthma medication Clin. Immunother. 6 1996 273 299
3. D. Prime, P.J. Atkins, A. Slater, and B. Sumby Review of dry powder inhalers Adv. Drug Delivery Rev. 26 1997 51 58
4. P.L. Smith Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery J. Controlled Release 46 1997 99 106
5. P.L. Nicklin, D. Bayley, J. Giddings, S.J. Craig, L.L. Cummins, J.G. Hastewell, and J.A. Phillips Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes Pharm. Res. 15 1998 583 591
6. T. Nakate, H. Yoshida, A. Ohike, Y. Tokunaga, R. Ibuki, and Y. Kawashima Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with β-cyclodextrin Eur. J. Pharm. Biopharm. 55 2003 147 154
7. T. Nakate, H. Yoshida, A. Ohike, Y. Tokunaga, R. Ibuki, and Y. Kawashima Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler® and its absorption in healthy volunteers J. Controlled Release 97 2004 18 29
8. Y. Kawashima, T. Serigano, T. Hino, H. Yamamoto, and H. Takeuchi Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate Int. J. Pharm. 172 1998 178 188
9. F. Podczeck Evaluation of the adhesion properties of salbutamol sulphate to inhaler materials Pharm. Res. 15 1998 806 808
10. K. Iida, A. Otsuka, K. Danjo, and H. Sunada Measurement of adhesive force between particles and polymer-films Chem. Pharm. Bull. 40 1992 189 192
11. Y. Shimada, Y. Yonezawa, and H. Sunada Measurement and evaluation of the adhesive force between particles by the direct separation method J. Pharm. Sci. 92 2003 560 568
12. T. Ogura, Y. Furuya, and S. Matsuura HPMC capsules - an alternative to gelatin Pharm. Technol. Eur. 10 1998 32 42
13. N.M. Kassem, M.A. Shamat, and C. Duval The inspirable properties of a carrier-free dry powder aerosol formulation J. Pharm. Pharmacol. 43 1991 75P
14. H. Steckel, and B.W. Müler In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices Int. J. Pharm. 154 1997 19 29
15. M.V. Oort, B. Downey, and W. Roberts Verification of operating the Andersen cascade impactor at different flow rates Pharmacopeial Forum 22 1996 2211 2215
16. Y. Kawashima, A. Imai, H. Yamamoto, K. Kamiya, and T. Hino Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process Powder Technol. 130 2003 283 289